Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's Jubilant Completes Acquisition of U.S. Co Hollister-Stier (India)

This article was originally published in PharmAsia News

Executive Summary

Jubilant Organosys, a pharmaceutical research company in India, has finalized the purchase of U.S.-based Hollister-Stier Laboratories for $122.5 million in an all-cash transaction. Jubilant is looking to strengthen its growing global expertise in custom-research and manufacturing services. (Click here for more

You may also be interested in...



Jubilant Profits Spurred By Foreign Business

Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31

India’s Jubilant Organosys Nets $92 Million CRAMS Order For 2008

NEW DELHI - India's growing success in the pharmaceutical custom research and manufacturing services sector is demonstrated by Jubilant Organosys netting CRAMS contracts totaling $92 million for 2008, with most contracts coming from Japan, China, the U.S. and Europe, the Uttar Pradesh-based manufacturer said Feb. 2

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel